Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 17/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taxuspine J SCHEMBL32665717 | 0.75 | NLRP3 (0.41) | ABCB1NLRP3CYP2C19 | |
| SCHEMBL44567 | 0.74 | NLRP3 (0.43) | ABCB1NLRP3CYP2C19 | |
| SCHEMBL31384147 | 0.74 | NLRP3 (0.43) | ABCB1NLRP3CYP2C19 | |
| SCHEMBL44737 | 0.73 | NLRP3 (0.47) | ABCB1NLRP3CYP2C19 | |
| Taxuspine A SCHEMBL31565642 | 0.71 | ABCB1 (0.41) | ABCB1NLRP3 | |
| SCHEMBL29425006 | 0.70 | NLRP3 (0.38) | ABCB1NLRP3CYP2C19 | |
| SCHEMBL44183 | 0.70 | ABCB1 (0.41) | ABCB1NLRP3 | |
| Taxagifine SCHEMBL29520283 | 0.69 | ABCB1 (0.40) | ABCB1NLRP3CYP2C19 | |
| Taxagifine SCHEMBL28964410 | 0.69 | ABCB1 (0.40) | ABCB1NLRP3CYP2C19 | |
| SCHEMBL29786939 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710013-B2 | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use | ANGIOCHEM INC. (CA) | 2014-04-29 | — | — | US | claimed |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2018-01-18 | — | — | US | disclosed |
| EP-2588490-B1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2017-02-22 | — | — | EP | disclosed |
| US-20160263236-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| US-9161988-B2 | Multimeric peptide conjugates and uses thereof | ANGIOCHEM INC. (CA) | 2015-10-20 | — | — | US | disclosed |
| US-20150174267-A1 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS | ANGIOCHEM INC (CA) | 2015-06-25 | — | — | US | disclosed |
| US-8710013-B2 | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use | ANGIOCHEM INC. (CA) | 2014-04-29 | — | — | US | disclosed |
| US-20130280281-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| EP-2588490-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2013-05-08 | — | — | EP | disclosed |
| US-20120277158-A1 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS | ANGIOCHEM INC. (CA) | 2012-11-01 | — | — | US | disclosed |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | disclosed |
| WO-2012037687-A9 | THERAPEUTIC POLYPEPTIDES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012037687-A1 | THERAPEUTIC POLYPEPTIDES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012000118-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| US-20110112036-A1 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE | ANGIOCHEM INC. (CA) | 2011-05-12 | — | — | US | disclosed |
| WO-2011041897-A1 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS | ANGIOCHEM INC. (CA) | 2011-04-14 | — | — | WO | disclosed |
| EP-2279008-A1 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE | Angiochem Inc. (CA) | 2011-02-02 | — | — | EP | disclosed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2009127072-A1 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE | ANGIOCHEM INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | LNPEP, DNPEP, VIP | ABCB1 101/4885NLRP3 1887/4885CYP2C19 4507/4885 |
| US-20110112036-A1 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE | PGA5, KIF5A, ABCB11 | ABCB1 8/4885NLRP3 4740/4885CYP2C19 1007/4885 |
| US-20130280281-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | ABCB1 112/4885NLRP3 3107/4885CYP2C19 3741/4885 |
| US-20120277158-A1 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS | GBA1, SLC47A1, GAA | ABCB1 92/4885NLRP3 4488/4885CYP2C19 4383/4885 |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | ABCB1 112/4885NLRP3 3107/4885CYP2C19 3741/4885 |
| US-20160263236-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | ABCB1 112/4885NLRP3 3107/4885CYP2C19 3741/4885 |
| US-20150174267-A1 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS | GBA1, SLC47A1, GAA | ABCB1 92/4885NLRP3 4488/4885CYP2C19 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.